BioCryst Pharmaceuticals, Inc. (BCRX): Neutral Rating Reiterated

BCRX – Needham & Co. reiterates Hold rating. Stock price at the time of this analyst call was $5.87.


Update: As of Aug. 22, 2017, this analyst call has returned -25.38%.


Key Facts Surrounding This News Item


  • BCRX had a POWR Rating of D (Sell) coming into today.
  • BCRX was 2.55% above its 10-Day Moving Average coming into today.
  • BCRX was -3.27% below its 20-Day Moving Average coming into today.
  • BCRX was -18.89% below its 50-Day Moving Average coming into today.
  • BCRX was -13.59% below its 100-Day Moving Average coming into today.
  • BCRX was 1.13% above its 200-Day Moving Average coming into today.
  • BCRX had returned -7.27% year-to-date leading up to today’s news, versus a +6.38% return from the benchmark S&P 500 during the same period.

More Info About BioCryst Pharmaceuticals, Inc. (BCRX)


Biocryst Pharmaceuticals designs, optimizes and develops novel small molecule drugs that block key enzymes involved in rare diseases. The company was founded in 1986 and is based in Durham, North Carolina. View our full BCRX ticker page with ratings, news, and more.

BCRX at a Glance

BCRX Current POWR Rating™
Overall POWR Rating™
BCRX Current Price $4.38 4.04%
More BCRX Ratings, Data, and News

BCRX Price Reaction

The day of this event (May. 19, 2017)
BCRX Closing Price$5.48 6.64%
BCRX Volume1,103,800
1.67% from avg
Leading up to this event
BCRX 1-mo return11.33%
After this event
BCRX 1-day return12.02%
BCRX 3-day return14.42%
BCRX 5-day return1.73%

BCRX Price Chart



More BioCryst Pharmaceuticals, Inc. (BCRX) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All BCRX News
Page generated in 1.0767 seconds.